1. Catalog
  2. Telling the Twincretins Apart: GLP-1 and GIP in Ty ...
Telling the Twincretins Apart: GLP-1 and GIP in Type 2 Diabetes Management
(19)
Image For Activity Cover
Availability
Retired
2 Courses
Cost
$0.00
Credit Offered
No Credit Offered
  • Check out the Twitter Chat
  • Course Description
  • Target Audience
  • Learning Objectives
  • Accreditation Statement
  • Faculty and Disclosures
  • Recommended
On Friday, April 29, 2:00 – 3:00 PM EDT, we hosted a twitter chat on twincretin therapy. Catch up on the conversation via #TwincretinTakeover
This course features a podcast and accompanying journal article where experts highlight the newest research on the role of incretin actions (GIP and GLP-1) and glucagon in the pathophysiology of T2D. Experts address GIP physiology and the incretin effect beyond the individual role of GLP-1. Specifically, the synergetic role of GLP-1 and GIP and the benefits beyond glucose lowering, as well as newer therapies in development.
The intended audience for this activity is endocrinologists, especially those with specialty experience, who treat type 2 diabetes (T2D) in the United States.

Upon successful completion of these educational initiatives, participants should be better able to:

  1. Explain how incretins affect cellular function in multiple tissue types and contribute to glycemic control and other cardiometabolic effects.
  2. Compare and contrast historical research findings on GLP-1 and GIP modulation, with emphasis on a “GIP paradox” showing both pathophysiological and therapeutic potential.
  3. Define the roles of GLP-1- and GIP-targeting medications, separately or together, in T2D management using recent clinical trial data and treatment algorithms.

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.
Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Maintenance of Certification (MOC)
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1.00 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For questions about content or obtaining CME credit, please contact the Endocrine Society at info@endocrine.org

FACULTY AND DISCLOSURES
  • Dr. Zhenqi Liu, MD, Professor of Medicine, University of Virginia Health System
  • Dr. Marzieh Salehi, MD, Associate Professor of Medicine, University of Texas

STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the ACCME, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society's EBR faculty. There are no commercial supporters of this activity, and no commercial entities have had influence over the planning of this CME activity.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (eg, stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity regarding exposition or conclusion. 

The following faculty reported no relevant financial relationships:  Zhenqi Liu, MD ; and Marzieh Salehi, MD

The following Endocrine staff report no relevant financial relationships:Hannah Andrews, CAE; and Brandon Roccio. 

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This educational activity is supported by educational grant from Lilly USA, LLC.

   
     EndoCareers | Contact Us | Privacy Policy | Terms of Use CONNECT WITH US                
       © 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036      
 202.971.3636 | 888.363.6274       
   
Android App Download IOS App Download Powered By